Literature DB >> 3910312

Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade.

A U Krettli, L C Pontes de Carvalho.   

Abstract

Bloodstream trypomastigotes (BTry) of Trypanosoma cruzi were found to bind to their surface membrane in-vitro fragments of C3, namely C3b and/or C3bi. Different reagents specific for C3 were used: anti-C3c serum and anti-C3 monoclonal antibodies; bovine conglutinine and yeast particles. The BTry, isolated from acutely infected mice and maintained on a complement-free culture medium (TC-199), were strongly agglutinated by these reagents or formed clumps with the yeast only after being previously treated with fresh or heat inactivated normal human serum. It is suggested that the binding of C3b fragments to the parasite membrane may influence the extent or the nature of the early events during T. cruzi infection allowing the BTry to escape complement destruction by the alternative complement pathway.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3910312      PMCID: PMC1577450     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Induction of capping in blood-stage trypomastigotes of Trypanosoma cruzi by human anti-Trypanosoma cruzi antibodies.

Authors:  G A Schmuñis; A Szarfman; T Langembach; W de Souza
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

2.  Tissue tropism of different Trypanosoma cruzi strains.

Authors:  R C Melo; Z Brener
Journal:  J Parasitol       Date:  1978-06       Impact factor: 1.276

3.  The in vitro interaction of Trypanosoma cruzi bloodstream forms and mouse peritoneal macrophages.

Authors:  A Alcantara; Z Brener
Journal:  Acta Trop       Date:  1978-09       Impact factor: 3.112

4.  Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis.

Authors:  A U Krettli; P Weisz-Carrington; R S Nussenzweig
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

5.  Protective effects of specific antibodies in Trypanosoma cruzi infections.

Authors:  A U Krettli; Z Brener
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

6.  Effects of complement depletion in experimental chagas disease: immune lysis of virulent blood forms of Trypanosoma cruzi.

Authors:  D B Budzko; M C Pizzimenti; F Kierszenbaum
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

7.  Trypanosoma cruzi. Factors modifying ingestion and fate of blood form trypomastigotes.

Authors:  N Nogueira; S Chaplan; Z Cohn
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

8.  Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.

Authors:  P J Lachmann; M K Pangburn; R G Oldroyd
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

9.  Trypanosoma cruzi: mechanism of entry and intracellular fate in mammalian cells.

Authors:  N Nogueira; Z Cohn
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

10.  Trypanosoma cruzi: in vitro induction of macrophage microbicidal activity.

Authors:  N Nogueira; Z A Cohn
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  4 in total

1.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Inefficient complement system clearance of Trypanosoma cruzi metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells.

Authors:  Igor Cestari; Marcel I Ramirez
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

3.  Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.

Authors:  G M Krautz; L M Galvão; J R Cançado; A Guevara-Espinoza; A Ouaissi; A U Krettli
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

4.  Susceptibility of pathogenic and nonpathogenic Naegleria spp. to complement-mediated lysis.

Authors:  L Y Whiteman; F Marciano-Cabral
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.